


# PRODUCT INFORMATION



## Fluvastatin

Item No. 10010334

**CAS Registry No.:** 93957-54-1  
**Formal Name:** 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid  
**MF:** C<sub>24</sub>H<sub>26</sub>FNO<sub>4</sub>  
**FW:** 411.5  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 236, 305 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Fluvastatin is supplied as a crystalline solid. A stock solution may be made by dissolving the fluvastatin in the solvent of choice. Fluvastatin is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of fluvastatin in these solvents is approximately 1, 14, and 20 mg/ml, respectively.

Fluvastatin is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, fluvastatin should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Fluvastatin has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

Fluvastatin is an inhibitor of HMG-CoA reductase ( $K_i = 0.3$  nM for the rat enzyme) that binds to the HMG-CoA binding site.<sup>1,2</sup> It also inhibits the human cytochrome P450 (CYP) isoform CYP2C9 ( $IC_{50} = 100$  nM).<sup>3</sup> Fluvastatin (2 mg/kg per day) inhibits increases in serum cholesterol, triglycerides, phospholipids, and thiobarbituric acid-reactive substances (TBARS) levels, as well as vascular angiotensin converting enzyme (ACE) activity in rabbits fed a high-cholesterol diet.<sup>4</sup> It increases survival in a mouse model of myocardial infarction when administered at a dose of 10 mg/kg per day.<sup>5</sup> Formulations containing fluvastatin have been used in the treatment of hypercholesterolemia and the prevention of cardiovascular disease.

### References

1. Istvan, E.S. and Deisenhofer, J. *Science* **292**(5519), 1160-1164 (2001).
2. Corsini, A., Maggi, F.M., and Catapano, A.L. *Pharmacol. Res.* **31**(1), 9-27 (1995).
3. Transon, C., Leemann, T., and Dayer, P. *Eur. J. Clin. Pharmacol.* **50**(3), 209-215 (1996).
4. Mitani, H., Bandoh, T., Ishikawa, J., et al. *Br. J. Pharmacol.* **119**(6), 1269-1275 (1996).
5. Hayashidani, S., Tsutsui, H., Shiomi, T., et al. *Circulation* **105**(7), 868-873 (2002).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 07/19/2018

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM